| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2454 |
| Trial ID | NCT04545762 |
| Disease | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Mantle Cell Lymphoma | Primary Mediastinal B-Cell Lymphoma | Follicular Lymphoma | Burkitt Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Lymphoplasmacytic Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma |
| Year | 2020 |
| Country | United States |
| Company sponsor | University of California, San Francisco |
| Other ID(s) | 19703|NCI-2020-06711 |
| Cohort 1 | |||||||||||
|
|||||||||||